ArticleAsian Pacific journal of cancer prevention : APJCP2025
Study the Impact of NADPH oxidase1,TNF-alpha and Cyclooxygenase-2 On Colon Cancer Patients.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColon cancer is a major health concern globally, being one of the most commonly diagnosed cancers. Inflammation and oxidative stress are critical factors contributing to its development and progression. Understanding the roles of key molecules such as NOX1, TNF-α, and COX-2 in these processes may provide insights into potential biomarkers for early detection and targeted therapy.
objectiveThis study aims to investigate the roles of NADPH oxidase 1 (NOX1), Tumor Necrosis Factor-alpha (TNF-α), and Cyclooxygenase-2 (COX-2) in colon cancer progression and their possible implications in the disease context.
methodsA comparative analysis was conducted involving 40 colon cancer patients (15 males, 25 females; aged 20-78 years) and 40 healthy controls (17 males, 23 females; aged 21-75 years). Blood samples were collected from participants between October 10, 2023, and February 18, 2024. The levels of NOX1, TNF-α, and COX-2 were measured using the enzyme-linked immunosorbent assay (ELISA) method.
resultsThe study found significantly elevated levels of TNF-α in colon cancer patients (100.9-454.3 ng/L) compared to healthy controls (24.85-216.9 ng/L). Additionally, COX-2 levels were markedly higher in patients (239.4-690.53 units/L) than in controls (23.78-115.5 units/L). NOX1 levels were also elevated in cancer patients (4.0-14.92) relative to healthy subjects (0.89-9.39). These findings suggest an association between increased levels of TNF-α, COX-2, and NOX1 with a higher risk of colon cancer.
conclusionThe findings suggest that elevated levels of TNF-α, COX-2, and NOX1 may be associated with the progression of colon cancer, indicating their potential involvement in the disease. Specifically, higher levels of TNF-α and COX-2 could be linked to increased cancer cell proliferation and metastasis, while elevated NOX1 levels might be related to oxidative stress and cellular transformation in colon cancer patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.